close

Agreements

Date: 2018-08-23

Type of information: Research agreement

Compound: tumor-specific targets and natural T-cell receptors (TCRs)

Company: Bluebird bio (USA - MA) Gritstone Oncology (USA - CA)

Therapeutic area: Cancer - Oncology

Type agreement: research - development - commercialisation

Action mechanism: cell therapy.

Disease:

Details:

  • • On August 23, 2018, bluebird bio and Gritstone Oncology announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy. Gritstone Oncology will leverage its proprietary EDGE™ artificial intelligence platform to analyze specific tumor types to identify tumor-specific targets and natural T-cell receptors (TCRs) directed to those targets for use in bluebird bio’s established cell therapy platforms. bluebird bio will conduct all development, manufacturing and commercial activities. Gritstone Oncology will utilize its proprietary technology platform to enable patient selection for clinical development of such therapies.
  • Under the terms of the agreement, Gritstone Oncology will provide 10 tumor-specific targets across several tumor types and, in certain cases, TCRs directed to those targets to bluebird bio.
       

Financial terms:

  • Gritstone Oncology will receive $20 million in an upfront payment and an additional $10 million in the form of a Series C preferred equity investment. In addition, Gritstone Oncology is eligible for significant development, regulatory and commercial milestones on any therapies, and tiered royalties on certain approved therapies.

Latest news:

Is general: Yes